Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CytoDyn Inc.CYDY · Entity 5856 | Chief Financial Officer | March 20, 2026 | March 24, 2026 |
| FibroBiologics, Inc.FBLG · Entity 7875 | Director | June 23, 2026 | June 24, 2026 |
| HERON THERAPEUTICS, INC. /DE/HRTX · Entity 7133 | CFO & SVP, Finance | December 19, 2019 | December 23, 2019 |
| INNOVUS PHARMACEUTICALS, INC.INNV · Entity 151567 | CHIEF FINANCIAL OFFICER | September 06, 2016 | November 21, 2016 |
| Kura Oncology, Inc.KURA · Entity 4871 | Director | June 22, 2021 | June 23, 2021 |
| MABVAX THERAPEUTICS HOLDINGS, INC.MBVX · Entity 167746 | Director | May 19, 2017 | May 23, 2017 |
| TuHURA Biosciences, Inc./NVHURA · Entity 6601 | Director | February 12, 2026 | February 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CytoDyn Inc.
Report date March 20, 2026 · Filed March 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-qualified stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.28 · Expires 2036-03-20 | Direct | 4,874,691 |
Reported balance
After 2026-03-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-20 · Grant · Acquired 4,874,691 · Balance 4,874,691 F1: This grant was approved by the Company's Compensation Committee on March 20, 2026, and represents the annual grant to the individual for fiscal year 2026 consistent with past practice in recent years. This award was made in compliance with, and uses shares that are specifically reserved for issuance to employees, directors, and certain outside consultants under, the Issuer's 2012 Equity Incentive Plan, as amended (the "2012 Plan"). F2: 1,218,672 shares will vest on March 20, 2027, and the balance will vest in approximately equal installments on the same day of each month of Continuous Service (as the term is defined in the 2012 Plan) beginning April 2027 through March 2030. |
Filing footnotes · ownership attribution and instrument terms
F1: This grant was approved by the Company's Compensation Committee on March 20, 2026, and represents the annual grant to the individual for fiscal year 2026 consistent with past practice in recent years. This award was made in compliance with, and uses shares that are specifically reserved for issuance to employees, directors, and certain outside consultants under, the Issuer's 2012 Equity Incentive Plan, as amended (the "2012 Plan").
F2: 1,218,672 shares will vest on March 20, 2027, and the balance will vest in approximately equal installments on the same day of each month of Continuous Service (as the term is defined in the 2012 Plan) beginning April 2027 through March 2030.
FibroBiologics, Inc.
Report date June 23, 2026 · Filed June 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.75 · Expires 2036-06-22 | Direct | 30,803 |
Reported balance
After 2026-06-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-23 · Grant · Acquired 30,803 · Balance 30,803 F1: The options will vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: The options will vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual meeting.
HERON THERAPEUTICS, INC. /DE/
Report date December 19, 2019 · Filed December 23, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.02 · Expires 2029-12-19 | Direct | 100,000 |
Reported balance
After 2019-12-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-12-19 · Grant · Acquired 100,000 · Balance 100,000 F1: The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the date of grant.
INNOVUS PHARMACEUTICALS, INC.
Report date September 06, 2016 · Filed November 21, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock unitsSEC Table II · derivative / convertible security · Expires 2026-11-16 | Direct | 2,500,000 |
Reported balance
After 2016-09-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2016-09-06 · Grant · Acquired 2,500,000 · Balance 2,500,000 F1: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. F2: The Reporting Person was granted a Restricted Stock Unit on September 6, 2016 of 2,500,000 shares, which shall vest according to the following schedule: 1/3 after one year of employment with the Issuer and then in equal quarterly increments over the next eight quarters upon continuous employment with the Company. F3: These restricted stock units were granted pursuant to the Issuer's 2016 Equity Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents the right to receive, at settlement, one share of common stock.
F2: The Reporting Person was granted a Restricted Stock Unit on September 6, 2016 of 2,500,000 shares, which shall vest according to the following schedule: 1/3 after one year of employment with the Issuer and then in equal quarterly increments over the next eight quarters upon continuous employment with the Company.
F3: These restricted stock units were granted pursuant to the Issuer's 2016 Equity Incentive Plan.
Kura Oncology, Inc.
Report date June 22, 2021 · Filed June 23, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $21.54 · Expires 2031-06-21 | Direct | 23,000 |
Reported balance
After 2021-06-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-22 · Grant · Acquired 23,000 · Balance 23,000 F1: This option vests in full on the one year anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests in full on the one year anniversary of the date of grant.
MABVAX THERAPEUTICS HOLDINGS, INC.
Report date May 19, 2017 · Filed May 23, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.80 · Expires 2027-05-19 | Direct | 50,000 |
Reported balance
After 2017-05-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-05-19 · Grant · Acquired 50,000 · Balance 50,000 F1: The option is fully vested and exercisable and was issued pursuant to conditions of the Letter Agreement, dated May 15, 2017, by and between the Company and the lead investor in connection with the Company's public offering completed on May 19, 2017, and filed with the Securities and Exchange Commission on May 22, 2017 as Exhibit A of Exhibit 10.2 of the Company's Quarterly Report on Form 10-Q. |
Filing footnotes · ownership attribution and instrument terms
F1: The option is fully vested and exercisable and was issued pursuant to conditions of the Letter Agreement, dated May 15, 2017, by and between the Company and the lead investor in connection with the Company's public offering completed on May 19, 2017, and filed with the Securities and Exchange Commission on May 22, 2017 as Exhibit A of Exhibit 10.2 of the Company's Quarterly Report on Form 10-Q.
TuHURA Biosciences, Inc./NV
Report date February 12, 2026 · Filed February 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.29 · Expires 2036-02-12 | Direct | 156,240 |
Reported balance
After 2026-02-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-12 · Grant · Acquired 156,240 · Balance 156,240 F1: Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan. One-third of the stock options become exercisable on the first, second, and third anniversaries of February 12, 2026. |
| Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.11 · Expires 2035-01-02 | Direct | 51,275 |
Reported balance
Holding disclosure · report date 2026-02-12 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 51,275 F2: Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan previously granted on January 2, 2025. One-third of the stock options become exercisable on the first, second, and third anniversaries of January 2, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan. One-third of the stock options become exercisable on the first, second, and third anniversaries of February 12, 2026.
F2: Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan previously granted on January 2, 2025. One-third of the stock options become exercisable on the first, second, and third anniversaries of January 2, 2025.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Aravive, Inc.
Report date April 08, 2020 · Filed April 09, 2020
Section 16 reporting ended · disclosed 2020-04-09. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
CombiMatrix Corp
Report date November 14, 2017 · Filed November 16, 2017
Section 16 reporting ended · disclosed 2017-11-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2017-11-14 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2017-11-14 · Disposition to issuer · Disposed 2,001 · Balance 6,618 F1: Represents common stock of the issuer underlying restricted stock units that were cancelled in the merger pursuant to merger agreement between issuer and Invitae Corporation in exchange for 1,737 shares of Invitae common stock having a market value of $7.86 per share on the effective date of the merger. Row 2 · 2017-11-14 · Other · Disposed 6,618 · Balance 0 F2: Disposed of pursuant to merger agreement between issuer and Invitae Corporation in exchange for 5,752 shares of Invitae common stock having a market value of $7.86 per share on the effective date of the merger. |
| Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $46.80 · Expires 2018-12-20 | Direct | 0 |
Reported balance
After 2017-11-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-11-14 · Other · Acquired 1,619 · Balance 0 F3: This warrant was assumed by Invitae in the merger and replaced with a warrant to purchase 1,407 shares of Invitae common stock for $53.84 per share. F2: Disposed of pursuant to merger agreement between issuer and Invitae Corporation in exchange for 5,752 shares of Invitae common stock having a market value of $7.86 per share on the effective date of the merger. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents common stock of the issuer underlying restricted stock units that were cancelled in the merger pursuant to merger agreement between issuer and Invitae Corporation in exchange for 1,737 shares of Invitae common stock having a market value of $7.86 per share on the effective date of the merger.
F2: Disposed of pursuant to merger agreement between issuer and Invitae Corporation in exchange for 5,752 shares of Invitae common stock having a market value of $7.86 per share on the effective date of the merger.
F3: This warrant was assumed by Invitae in the merger and replaced with a warrant to purchase 1,407 shares of Invitae common stock for $53.84 per share.
Esperion Therapeutics, Inc.
Report date July 13, 2026 · Filed July 13, 2026
Section 16 reporting ended · disclosed 2026-07-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-07-13 transaction · row 1
1 source rowRow 1 · 2026-07-13 · Disposition to issuer · Disposed 85,153 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 1, 2026, by and among the Issuer, Essence Parent Inc., a Delaware corporation ("Parent") and Essence MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent ("MergerCo"), pursuant to which, on July 13, 2026 (the "Effective Time"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. F2: At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock") was converted into the right to receive (a) an amount in cash equal to $3.16 per share, without interest (the "per share cash consideration"), and (b) one contractual contingent value right per share (each, a "CVR" and, together with the per share cash consideration, the "merger consideration"), representing the right to participate in contingent payments in cash, without interest, upon the achievement of certain milestones, subject to any applicable withholding taxes. From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled. F3: Includes 79,873 restricted stock units (each, a "RSU"). At the Effective Time, each RSU with respect to Common Stock outstanding immediately prior to the Effective Time vested in full (to the extent then-unvested), and was canceled and converted into the right to receive, with respect to each share of Common Stock subject to such RSU immediately prior to the effective time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the per share cash consideration, plus (b) one CVR, subject to certain exceptions. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.41 · Expires 2035-04-01 | Direct | 0 |
Reported balance
After 2026-07-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-13 · Disposition to issuer · Disposed 40,000 · Balance 0 F4: At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR. F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 1, 2026, by and among the Issuer, Essence Parent Inc., a Delaware corporation ("Parent") and Essence MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent ("MergerCo"), pursuant to which, on July 13, 2026 (the "Effective Time"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.87 · Expires 2035-05-29 | Direct | 0 |
Reported balance
After 2026-07-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-13 · Disposition to issuer · Disposed 7,040 · Balance 0 F4: At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR. F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 1, 2026, by and among the Issuer, Essence Parent Inc., a Delaware corporation ("Parent") and Essence MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent ("MergerCo"), pursuant to which, on July 13, 2026 (the "Effective Time"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 1, 2026, by and among the Issuer, Essence Parent Inc., a Delaware corporation ("Parent") and Essence MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent ("MergerCo"), pursuant to which, on July 13, 2026 (the "Effective Time"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.
F2: At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock") was converted into the right to receive (a) an amount in cash equal to $3.16 per share, without interest (the "per share cash consideration"), and (b) one contractual contingent value right per share (each, a "CVR" and, together with the per share cash consideration, the "merger consideration"), representing the right to participate in contingent payments in cash, without interest, upon the achievement of certain milestones, subject to any applicable withholding taxes. From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled.
F3: Includes 79,873 restricted stock units (each, a "RSU"). At the Effective Time, each RSU with respect to Common Stock outstanding immediately prior to the Effective Time vested in full (to the extent then-unvested), and was canceled and converted into the right to receive, with respect to each share of Common Stock subject to such RSU immediately prior to the effective time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the per share cash consideration, plus (b) one CVR, subject to certain exceptions.
F4: At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 13, 2026 Filed Jul 13, 2026 20:06 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | Disposition to issuerStock Option (right to buy) · Derivative | 7,040 | Not disclosed Strike: $0.87 | Not disclosed |
DisclosureSEC source: 0001628280-26-048014 · wk-form4_1783973172.xml · derivative · entry 3 Hoffman Robert E. · CIK 0001166288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,040 shares Expires 2035-05-29 F4 · derivative.exercise_price: At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR. F1 · kind: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 1, 2026, by and among the Issuer, Essence Parent Inc., a Delaware corporation ("Parent") and Essence MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent ("MergerCo"), pursuant to which, on July 13, 2026 (the "Effective Time"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. F4 · price: At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR. F4 · derivative.exercise_date: At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR. Read SEC document |
| July 13, 2026 Filed Jul 13, 2026 20:06 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | Disposition to issuerStock Option (right to buy) · Derivative | 40,000 | Not disclosed Strike: $1.41 | Not disclosed |
DisclosureSEC source: 0001628280-26-048014 · wk-form4_1783973172.xml · derivative · entry 2 Hoffman Robert E. · CIK 0001166288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2035-04-01 F4 · derivative.exercise_price: At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR. F1 · kind: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 1, 2026, by and among the Issuer, Essence Parent Inc., a Delaware corporation ("Parent") and Essence MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent ("MergerCo"), pursuant to which, on July 13, 2026 (the "Effective Time"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. F4 · price: At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR. F4 · derivative.exercise_date: At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR. Read SEC document |
| July 13, 2026 Filed Jul 13, 2026 20:06 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | Disposition to issuerCommon Stock | 85,153 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-048014 · wk-form4_1783973172.xml · nonDerivative · entry 1 Hoffman Robert E. · CIK 0001166288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 1, 2026, by and among the Issuer, Essence Parent Inc., a Delaware corporation ("Parent") and Essence MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent ("MergerCo"), pursuant to which, on July 13, 2026 (the "Effective Time"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. F2 · shares: At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock") was converted into the right to receive (a) an amount in cash equal to $3.16 per share, without interest (the "per share cash consideration"), and (b) one contractual contingent value right per share (each, a "CVR" and, together with the per share cash consideration, the "merger consideration"), representing the right to participate in contingent payments in cash, without interest, upon the achievement of certain milestones, subject to any applicable withholding taxes. From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled. F3 · shares: Includes 79,873 restricted stock units (each, a "RSU"). At the Effective Time, each RSU with respect to Common Stock outstanding immediately prior to the Effective Time vested in full (to the extent then-unvested), and was canceled and converted into the right to receive, with respect to each share of Common Stock subject to such RSU immediately prior to the effective time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the per share cash consideration, plus (b) one CVR, subject to certain exceptions. F2 · price: At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock") was converted into the right to receive (a) an amount in cash equal to $3.16 per share, without interest (the "per share cash consideration"), and (b) one contractual contingent value right per share (each, a "CVR" and, together with the per share cash consideration, the "merger consideration"), representing the right to participate in contingent payments in cash, without interest, upon the achievement of certain milestones, subject to any applicable withholding taxes. From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled. F3 · price: Includes 79,873 restricted stock units (each, a "RSU"). At the Effective Time, each RSU with respect to Common Stock outstanding immediately prior to the Effective Time vested in full (to the extent then-unvested), and was canceled and converted into the right to receive, with respect to each share of Common Stock subject to such RSU immediately prior to the effective time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the per share cash consideration, plus (b) one CVR, subject to certain exceptions. Read SEC document |
| June 23, 2026 Filed Jun 24, 2026 00:02 UTC | FibroBiologics, Inc. FBLG · Entity 7875 | GrantStock Option (Right to Buy) · Derivative | 30,803 | $0.00 Strike: $0.75 | $0.00 |
DisclosureSEC source: 0001493152-26-029851 · ownership.xml · derivative · entry 1 Hoffman Robert E. · CIK 0001166288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,803 Underlying: Common Stock · 30,803 shares Expires 2036-06-22 F1 · derivative.exercise_date: The options will vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual meeting. Read SEC document |
| May 28, 2026 Filed Jun 1, 2026 20:23 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | GrantCommon Stock | 79,873 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-039525 · wk-form4_1780345413.xml · nonDerivative · entry 1 Hoffman Robert E. · CIK 0001166288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,153 F1 · shares: The awards vest in full on the earlier of (i) May 28, 2027 and (ii) the Issuer's next annual meeting of stockholders following May 28, 2026. Read SEC document |
| March 20, 2026 Filed Mar 24, 2026 21:22 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantNon-qualified stock option (right to buy) · Derivative | 4,874,691 | $0.00 Strike: $0.28 | $0.00 |
DisclosureSEC source: 0001104659-26-033958 · tm269618-4_4seq1.xml · derivative · entry 1 Hoffman Robert E. · CIK 0001166288 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,874,691 Underlying: Common Stock · 4,874,691 shares Expires 2036-03-20 F1 · shares: This grant was approved by the Company's Compensation Committee on March 20, 2026, and represents the annual grant to the individual for fiscal year 2026 consistent with past practice in recent years. This award was made in compliance with, and uses shares that are specifically reserved for issuance to employees, directors, and certain outside consultants under, the Issuer's 2012 Equity Incentive Plan, as amended (the "2012 Plan"). F2 · derivative.exercise_date: 1,218,672 shares will vest on March 20, 2027, and the balance will vest in approximately equal installments on the same day of each month of Continuous Service (as the term is defined in the 2012 Plan) beginning April 2027 through March 2030. Read SEC document |
| February 12, 2026 Filed Feb 17, 2026 21:09 UTC | TuHURA Biosciences, Inc./NV HURA · Entity 6601 | GrantOptions (Right to Buy) · Derivative | 156,240 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0000897069-26-000360 · form4.xml · derivative · entry 1 Hoffman Robert E. · CIK 0001166288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 156,240 Underlying: Common Stock · 156,240 shares Expires 2036-02-12 F1 · date: Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan. One-third of the stock options become exercisable on the first, second, and third anniversaries of February 12, 2026. F1 · derivative.exercise_date: Represents an annual option grant under the TuHURA Biosciences, Inc. 2024 Equity Incentive Plan. One-third of the stock options become exercisable on the first, second, and third anniversaries of February 12, 2026. Read SEC document |
| June 12, 2025 Filed Jun 12, 2025 23:23 UTC | FibroBiologics, Inc. FBLG · Entity 7875 | GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $0.87 | $0.00 |
DisclosureSEC source: 0001641172-25-014934 · ownership.xml · derivative · entry 1 Hoffman Robert E. · CIK 0001166288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2025-06-11 F1 · derivative.exercise_date: The options will vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual meeting. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 20:09 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | GrantStock Option (right to buy) · Derivative | 7,040 | $0.00 Strike: $0.87 | $0.00 |
DisclosureSEC source: 0001628280-25-028828 · wk-form4_1748894965.xml · derivative · entry 2 Hoffman Robert E. · CIK 0001166288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,040 Underlying: Common Stock · 7,040 shares Expires 2035-05-29 F1 · derivative.exercise_date: The awards vest in full on the earlier of (i) May 29, 2026 and (ii) the Issuer's next annual meeting of stockholders following May 29, 2025. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 20:09 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | GrantCommon Stock | 5,280 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-028828 · wk-form4_1748894965.xml · nonDerivative · entry 1 Hoffman Robert E. · CIK 0001166288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,280 F1 · shares: The awards vest in full on the earlier of (i) May 29, 2026 and (ii) the Issuer's next annual meeting of stockholders following May 29, 2025. Read SEC document |
| May 15, 2025 Filed May 23, 2025 00:31 UTC | CytoDyn Inc. CYDY · Entity 5856 | GrantNon-qualified stock option (right to buy) · Derivative | 1,000,000 | $0.00 Strike: $0.41 | $0.00 |
DisclosureSEC source: 0001104659-25-052122 · tm2515909-2_4seq1.xml · derivative · entry 1 Hoffman Robert E. · CIK 0001166288 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Common Stock · 1,000,000 shares Expires 2035-05-15 F1 · shares: This grant was approved by the Company's Compensation Committee effective May 15, 2025, pursuant to the Issuer's 2012 Equity Incentive Plan, as amended (the "Plan"). F2 · derivative.exercise_date: 250,000 shares will vest on May 15, 2026, and the balance will vest in equal monthly installments at the conclusion of each month of Continuous Service (as the term is defined in the Plan ) from May 2026 through April 2029. Read SEC document |
| April 01, 2025 Filed Apr 2, 2025 20:19 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $1.41 | $0.00 |
DisclosureSEC source: 0001628280-25-016196 · wk-form4_1743625147.xml · derivative · entry 1 Hoffman Robert E. · CIK 0001166288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2035-04-01 F1 · derivative.exercise_date: The awards vest over a three (3) year period in equal annual installments the first of which will be April 1, 2026. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 22:08 UTC | TuHURA Biosciences, Inc./NV HURA · Entity 6601 | GrantOptions (Right to Buy) · Derivative | 51,275 | $0.00 Strike: $4.11 | $0.00 |
DisclosureSEC source: 0000897069-25-000037 · form4.xml · derivative · entry 1 Hoffman Robert E. · CIK 0001166288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,275 Underlying: Common Stock · 51,275 shares Expires 2035-01-02 F1 · date: Represents an annual option grant under the TuHURA Biosciences, Inc. Non-Employee Director Compensation Program. One-third of the stock options become exercisable on the first, second, and third anniversaries of January 2, 2025. F1 · derivative.exercise_date: Represents an annual option grant under the TuHURA Biosciences, Inc. Non-Employee Director Compensation Program. One-third of the stock options become exercisable on the first, second, and third anniversaries of January 2, 2025. Read SEC document |
| August 27, 2024 Filed Aug 27, 2024 23:53 UTC | FibroBiologics, Inc. FBLG · Entity 7875 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $1.73 | $0.00 |
DisclosureSEC source: 0001493152-24-034068 · ownership.xml · derivative · entry 1 Hoffman Robert E. · CIK 0001166288 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2034-08-26 F1 · derivative.exercise_date: The options will vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next annual meeting. Read SEC document |
| August 30, 2023 Filed Sep 1, 2023 22:00 UTC | TuHURA Biosciences, Inc./NV KTRA · Entity 6601 | GrantOptions (Right to Buy) · Derivative | 23,142 | $0.00 Strike: $4.66 | $0.00 |
DisclosureSEC source: 0001493152-23-031537 · ownership.xml · derivative · entry 1 Hoffman Robert E. · CIK 0001166288 · Director · President, CEO and Interim CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,142 Underlying: Common Stock · 23,142 shares Expires 2033-08-30 F1 · derivative.exercise_date: The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued employment, 25% of the options vest on August 30, 2024, with the remaining shares vesting in 36 equal monthly installments commencing on September 30, 2024. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 20:05 UTC | TuHURA Biosciences, Inc./NV KTRA · Entity 6601 | GrantCommon Stock, par value $0.001 per share | 59,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-23-019950 · ownership.xml · nonDerivative · entry 1 Hoffman Robert E. · CIK 0001166288 · Director · President, CEO, and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,902 F1 · shares: The Reporting Person was granted 59,800 restricted stock units, which will be settled in shares of the Issuer's common stock. The restricted stock units vest in full on June 1, 2024. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 20:30 UTC | TuHURA Biosciences, Inc./NV KTRA · Entity 6601 | GrantOption (right to buy) · Derivative | 1,200,634 | $0.00 Strike: $0.18 | $0.00 |
DisclosureSEC source: 0001493152-22-021170 · ownership.xml · derivative · entry 2 Hoffman Robert E. · CIK 0001166288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,200,634 Underlying: Common Stock · 1,200,634 shares Expires 2022-08-02 F2 · derivative.exercise_date: The option vests as to 25% on August 1, 2023 with the remainder to vest in 36 equal monthly installments thereafter. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 20:30 UTC | TuHURA Biosciences, Inc./NV KTRA · Entity 6601 | GrantCommon Stock | 400,145 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-021170 · ownership.xml · nonDerivative · entry 1 Hoffman Robert E. · CIK 0001166288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 455,145 F1 · shares: The Reporting Person was granted 400,145 restricted stock units, which will be settled in shares of the Issuer's common stock. The restricted stock units vest in 4 equal annual installments beginning on August 1, 2023. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:00 UTC | TuHURA Biosciences, Inc./NV KTRA · Entity 6601 | PurchaseCommon Stock | 55,000 | $0.47 | $25,795.00 |
DisclosureSEC source: 0000905718-22-000393 · kintara_fm4feb152022.xml · nonDerivative · entry 1 Hoffman Robert E. · CIK 0001166288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.4625 to $0.4697 per share, inclusive. The reporting person undertakes to provide to Kintara Therapeutics, Inc., any security holder of Kintara Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. Read SEC document |
| November 08, 2021 Filed Nov 10, 2021 21:18 UTC | TuHURA Biosciences, Inc./NV KTRA · Entity 6601 | GrantOptions (Right to Buy) · Derivative | 3,519,170 | $0.00 Strike: $0.96 | $0.00 |
DisclosureSEC source: 0000899243-21-043913 · doc4.xml · derivative · entry 1 HOFFMAN ROBERT · CIK 0001166288 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,519,170 Underlying: Common Stock · 3,519,170 shares Expires 2031-11-08 F1 · derivative.exercise_date: The option award was made to the reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to the reporting person's continued employment, the shares subject to the option shall vest as follows: 25% of the shares subject to the option shall vest on November 8, 2022, and the remainder shall vest in equal monthly installments over the following thirty-six (36) months. Read SEC document |
| September 22, 2021 Filed Sep 23, 2021 00:35 UTC | TuHURA Biosciences, Inc./NV KTRA · Entity 6601 | GrantOptions (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0000905718-21-001221 · kintara_fm4sep222021.xml · derivative · entry 1 HOFFMAN ROBERT · CIK 0001166288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-09-22 F1 · derivative.exercise_date: The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued service, the options vest in 12 equal monthly installments commencing on October 22, 2021. Read SEC document |
| June 22, 2021 Filed Jun 23, 2021 21:14 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 23,000 | $0.00 Strike: $21.54 | $0.00 |
DisclosureSEC source: 0001209191-21-042777 · doc4.xml · derivative · entry 1 HOFFMAN ROBERT · CIK 0001166288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2031-06-21 F1 · derivative.exercise_date: This option vests in full on the one year anniversary of the date of grant. Read SEC document |
| September 15, 2020 Filed Sep 18, 2020 01:05 UTC | TuHURA Biosciences, Inc./NV KTRA · Entity 6601 | GrantOptions (Right to Buy) · Derivative | 120,000 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0000905718-20-000967 · kintara_fm4sep152020.xml · derivative · entry 1 HOFFMAN ROBERT · CIK 0001166288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2030-09-15 F1 · derivative.exercise_date: The option award was made to reporting person pursuant to the 2017 Omnibus Equity Incentive Plan, as amended. Subject to continued service, the options vest in 12 equal monthly installments commencing on October 15, 2020 Read SEC document |
| June 26, 2020 Filed Jun 30, 2020 20:11 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | GrantOptions (Right to Buy) · Derivative | 39,567 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001213900-20-016308 · ownership.xml · derivative · entry 1 HOFFMAN ROBERT · CIK 0001166288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 39,567 shares Expires 2029-09-05 F1 · kind: On September 5, 2019, the reporting person received options to purchase 39,567 shares which were subject to stockholder approval of the increase in the number of shares authorized for issuance under the DelMar Pharmaceuticals, Inc. 2017 Omnibus Equity Incentive Plan, as amended, at the 2020 Annual Meeting of Stockholders. Stockholder approval of the increase was obtained on June 26, 2020. F2 · derivative.exercise_date: The shares subject to the option vest in twelve (12) equal monthly installments beginning on October 5, 2019. Read SEC document |
| June 24, 2020 Filed Jun 26, 2020 20:06 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 23,000 | $0.00 Strike: $17.97 | $0.00 |
DisclosureSEC source: 0001209191-20-039067 · doc4.xml · derivative · entry 1 HOFFMAN ROBERT · CIK 0001166288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2030-06-23 F1 · derivative.exercise_date: This option vests in full on the one year anniversary of the date of grant. Read SEC document |
| December 19, 2019 Filed Dec 23, 2019 21:28 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantEmployee Stock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $25.02 | $0.00 |
DisclosureSEC source: 0001209191-19-061794 · doc4.xml · derivative · entry 1 HOFFMAN ROBERT · CIK 0001166288 · CFO & SVP, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2029-12-19 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the date of grant. Read SEC document |
| September 12, 2019 Filed Sep 13, 2019 20:25 UTC | Aravive, Inc. ARAV · Entity 114535 | GrantStock Option · Derivative | 7,500 | $0.00 Strike: $5.77 | $0.00 |
DisclosureSEC source: 0000899243-19-023563 · doc4.xml · derivative · entry 1 HOFFMAN ROBERT · CIK 0001166288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2029-09-11 F1 · shares: These options vest pro rata on a monthly basis commencing on October 12, 2019 for the next 12 months with full vesting, if not fully vested at such time, on the date of the Aravive Inc.'s next annual meeting of stockholders. Read SEC document |
| September 05, 2019 Filed Sep 9, 2019 20:46 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | GrantOptions (Right to Buy) · Derivative | 35,433 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0000905718-19-000767 · delmarph_fm4sept52019.xml · derivative · entry 2 HOFFMAN ROBERT · CIK 0001166288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,433 Underlying: Common Stock · 35,433 shares Expires 2029-09-05 F2 · derivative.exercise_date: The shares subject to the option vest in twelve (12) equal monthly installments beginning on October 5, 2019. Read SEC document |
| September 05, 2019 Filed Sep 9, 2019 20:46 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | GrantOptions (Right to Buy) · Derivative | 39,567 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0000905718-19-000767 · delmarph_fm4sept52019.xml · derivative · entry 1 HOFFMAN ROBERT · CIK 0001166288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,567 Underlying: Common Stock · 39,567 shares Expires 2029-09-05 F1 · derivative.exercise_date: Subject to stockholder approval of the increase in the number of shares authorized for issuance under the DelMar Pharmaceuticals, Inc. 2017 Omnibus Equity Incentive Plan, as amended, at the next annual meeting, the shares subject to the option vest in twelve (12) equal monthly installments beginning on October 5, 2019. Read SEC document |
| June 25, 2019 Filed Jun 27, 2019 20:05 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 13,000 | $0.00 Strike: $19.55 | $0.00 |
DisclosureSEC source: 0001209191-19-039240 · doc4.xml · derivative · entry 1 HOFFMAN ROBERT · CIK 0001166288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2029-06-24 F1 · derivative.exercise_date: This option vests in full on the one year anniversary of the date of grant. Read SEC document |
| April 30, 2019 Filed May 1, 2019 22:32 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | Disposition to issuerPerformance Stock Units · Derivative | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-19-007626 · ownership.xml · derivative · entry 1 HOFFMAN ROBERT · CIK 0001166288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires 2022-07-07 F1 · derivative.exercise_price: Each performance stock unit represents the right to receive one share of common stock, to vest upon achievement of specified targets related to the Company's financial performance. Such performance stock units were unvested. F1 · derivative.exercise_date: Each performance stock unit represents the right to receive one share of common stock, to vest upon achievement of specified targets related to the Company's financial performance. Such performance stock units were unvested. Read SEC document |
| January 03, 2019 Filed Jan 8, 2019 02:24 UTC Amendment | Aravive, Inc. ARAV · Entity 114535 | GrantStock Option · Derivative | 4,688 | $0.00 Strike: $3.61 | $0.00 |
DisclosureSEC source: 0001213900-19-000327 · ownership.xml · derivative · entry 2 HOFFMAN ROBERT · CIK 0001166288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,688 Underlying: Common Stock · 4,688 shares Expires 2029-01-02 F1 · derivative.exercise_price: The reporting person is amending the Form 4 originally filed to report the correct exercise price, which is $3.61. The exercise price was incorrectly reported in the initial Form 4 due to a typographical error. F3 · shares: These options vest as follows: (i) 1,563 shares of common stock vest immediately upon grant and (ii) 625 will vest on a monthly basis over the next five months commencing on February 3, 2019 with full vesting, if not fully vested at such time, on the date of the Aravive Inc.'s next annual meeting of stockholders. F3 · derivative.exercise_date: These options vest as follows: (i) 1,563 shares of common stock vest immediately upon grant and (ii) 625 will vest on a monthly basis over the next five months commencing on February 3, 2019 with full vesting, if not fully vested at such time, on the date of the Aravive Inc.'s next annual meeting of stockholders. Read SEC document |
| January 03, 2019 Filed Jan 8, 2019 02:24 UTC Amendment | Aravive, Inc. ARAV · Entity 114535 | GrantStock Option · Derivative | 7,500 | $0.00 Strike: $3.61 | $0.00 |
DisclosureSEC source: 0001213900-19-000327 · ownership.xml · derivative · entry 1 HOFFMAN ROBERT · CIK 0001166288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2029-01-02 F1 · derivative.exercise_price: The reporting person is amending the Form 4 originally filed to report the correct exercise price, which is $3.61. The exercise price was incorrectly reported in the initial Form 4 due to a typographical error. F2 · shares: These options vest as follows: (i) 625 shares of common stock vest immediately upon grant and (ii) the balance will vest pro rata on a monthly basis over the next 33 months commencing on February 12, 2019. F2 · derivative.exercise_date: These options vest as follows: (i) 625 shares of common stock vest immediately upon grant and (ii) the balance will vest pro rata on a monthly basis over the next 33 months commencing on February 12, 2019. Read SEC document |
| January 03, 2019 Filed Jan 7, 2019 19:09 UTC | Aravive, Inc. ARAV · Entity 114535 | GrantStock Option · Derivative | 4,688 | $0.00 Strike: $3.69 | $0.00 |
DisclosureSEC source: 0001213900-19-000277 · ownership.xml · derivative · entry 2 HOFFMAN ROBERT · CIK 0001166288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,688 Underlying: Common Stock · 4,688 shares Expires 2029-01-02 F2 · shares: These options vest as follows: (i) 1,563 shares of common stock vest immediately upon grant and (ii) 625 will vest on a monthly basis over the next five months commencing on February 3, 2019 with full vesting, if not fully vested at such time, on the date of the Aravive Inc.'s next annual meeting of stockholders. F2 · derivative.exercise_date: These options vest as follows: (i) 1,563 shares of common stock vest immediately upon grant and (ii) 625 will vest on a monthly basis over the next five months commencing on February 3, 2019 with full vesting, if not fully vested at such time, on the date of the Aravive Inc.'s next annual meeting of stockholders. Read SEC document |
| January 03, 2019 Filed Jan 7, 2019 19:09 UTC | Aravive, Inc. ARAV · Entity 114535 | GrantStock Option · Derivative | 7,500 | $0.00 Strike: $3.69 | $0.00 |
DisclosureSEC source: 0001213900-19-000277 · ownership.xml · derivative · entry 1 HOFFMAN ROBERT · CIK 0001166288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2029-01-02 F1 · shares: These options vest as follows: (i) 625 shares of common stock vest immediately upon grant and (ii) the balance will vest pro rata on a monthly basis over the next 33 months commencing on February 12, 2019. F1 · derivative.exercise_date: These options vest as follows: (i) 625 shares of common stock vest immediately upon grant and (ii) the balance will vest pro rata on a monthly basis over the next 33 months commencing on February 12, 2019. Read SEC document |
| December 15, 2018 Filed Dec 19, 2018 01:07 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantEmployee Stock Option (Right to Buy) · Derivative | 71,000 | $0.00 Strike: $24.97 | $0.00 |
DisclosureSEC source: 0001209191-18-063349 · doc4.xml · derivative · entry 1 HOFFMAN ROBERT · CIK 0001166288 · CFO & SVP, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,000 Underlying: Common Stock · 71,000 shares Expires 2028-12-15 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the date of grant. Read SEC document |
| November 08, 2018 Filed Nov 13, 2018 21:37 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | GrantOptions (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $0.61 | $0.00 |
DisclosureSEC source: 0001213900-18-015511 · ownership.xml · derivative · entry 1 HOFFMAN ROBERT · CIK 0001166288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2028-11-08 F1 · derivative.exercise_date: The shares subject to the option vest in twelve (12) equal monthly installments beginning on December 8, 2018. Read SEC document |
| July 02, 2018 Filed Jul 4, 2018 01:03 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $15.30 | $0.00 |
DisclosureSEC source: 0001209191-18-041385 · doc4.xml · derivative · entry 5 HOFFMAN ROBERT · CIK 0001166288 · CFO & SVP, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 30,000 shares Expires 2027-04-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan dated as of May 30, 2018. F5 · derivative.exercise_date: Options vest and become exercisable with respect to 32,500 shares on the first anniversary of his first day of employment (the "Grant Date"), followed by 97,500 shares vesting ratably each month over the subsequent three years, such that 130,000 options will be fully vested on the four year anniversary of the Grant Date. Read SEC document |
| July 02, 2018 Filed Jul 4, 2018 01:03 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | SaleCommon Stock | 1,060 | $38.80 | $41,123.02 |
DisclosureSEC source: 0001209191-18-041385 · doc4.xml · nonDerivative · entry 4 HOFFMAN ROBERT · CIK 0001166288 · CFO & SVP, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,280 F2 · kind: The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan dated as of May 30, 2018. F4 · price: The range of sales prices received was $38.625 to $38.85. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information will be provided regarding the number of shares purchased or sold at each separate price. Read SEC document |
| July 02, 2018 Filed Jul 4, 2018 01:03 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | SaleCommon Stock | 28,940 | $38.15 | $1,104,107.30 |
DisclosureSEC source: 0001209191-18-041385 · doc4.xml · nonDerivative · entry 3 HOFFMAN ROBERT · CIK 0001166288 · CFO & SVP, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,340 F2 · kind: The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan dated as of May 30, 2018. F3 · price: The range of sales prices received was $37.60 to $38.60. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information will be provided regarding the number of shares purchased or sold at each separate price. Read SEC document |
| July 02, 2018 Filed Jul 4, 2018 01:03 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | Exercise / conversionCommon Stock | 30,000 | $15.30 | $459,000.00 |
DisclosureSEC source: 0001209191-18-041385 · doc4.xml · nonDerivative · entry 2 HOFFMAN ROBERT · CIK 0001166288 · CFO & SVP, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,280 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan dated as of May 30, 2018. Read SEC document |
| June 07, 2018 Filed Jun 8, 2018 20:09 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 13,000 | $0.00 Strike: $16.35 | $0.00 |
DisclosureSEC source: 0001209191-18-036658 · doc4.xml · derivative · entry 1 HOFFMAN ROBERT · CIK 0001166288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2028-06-06 F1 · derivative.exercise_date: This option vests in full on the one year anniversary of the date of grant. Read SEC document |
| April 30, 2018 Filed Jul 4, 2018 01:03 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | OtherCommon Stock | 744 | $13.22 | $9,833.82 |
DisclosureSEC source: 0001209191-18-041385 · doc4.xml · nonDerivative · entry 1 HOFFMAN ROBERT · CIK 0001166288 · CFO & SVP, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,280 F1 · kind: Represents shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan on April 30, 2018. Read SEC document |
| April 13, 2018 Filed Apr 17, 2018 20:15 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | GrantPerformance Stock Units · Derivative | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-18-004593 · f4041318hoffman_delmar.xml · derivative · entry 2 HOFFMAN ROBERT · CIK 0001166288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2022-07-07 F2 · derivative.exercise_price: Each performance stock unit represents the right to receive one share of common stock upon vesting of the unit based on achievement of specified targets related to the Company's financial performance. F2 · derivative.exercise_date: Each performance stock unit represents the right to receive one share of common stock upon vesting of the unit based on achievement of specified targets related to the Company's financial performance. Read SEC document |
| April 13, 2018 Filed Apr 17, 2018 20:15 UTC | TuHURA Biosciences, Inc./NV DMPI · Entity 6601 | GrantOptions (Right to Buy) · Derivative | 36,000 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001213900-18-004593 · f4041318hoffman_delmar.xml · derivative · entry 1 HOFFMAN ROBERT · CIK 0001166288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 36,000 shares Expires 2028-04-13 F1 · derivative.exercise_date: 12,000 options vest on March 31, 2019, and 3,000 options vest each three months thereafter starting June 30, 2019. Read SEC document |
| December 18, 2017 Filed Dec 20, 2017 21:13 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantEmployee Stock Option (Right to Buy) · Derivative | 56,667 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-17-066625 · doc4.xml · derivative · entry 2 HOFFMAN ROBERT · CIK 0001166288 · CFO & SVP, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,667 Underlying: Common Stock · 56,667 shares Expires 2027-12-18 F2 · derivative.exercise_date: The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the date of grant. Read SEC document |
| November 14, 2017 Filed Nov 16, 2017 22:53 UTC | CombiMatrix Corp CBMX · Entity 171845 | OtherWarrant (Right to Buy) · Derivative | 1,619 | Not disclosed Strike: $46.80 | Not disclosed |
DisclosureSEC source: 0001179110-17-014225 · edgar.xml · derivative · entry 3 HOFFMAN ROBERT · CIK 0001166288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,619 shares Expires 2018-12-20 F3 · price: This warrant was assumed by Invitae in the merger and replaced with a warrant to purchase 1,407 shares of Invitae common stock for $53.84 per share. F2 · derivative.exercise_date: Disposed of pursuant to merger agreement between issuer and Invitae Corporation in exchange for 5,752 shares of Invitae common stock having a market value of $7.86 per share on the effective date of the merger. Read SEC document |
| November 14, 2017 Filed Nov 16, 2017 22:53 UTC | CombiMatrix Corp CBMX · Entity 171845 | OtherCommon Stock | 6,618 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-17-014225 · edgar.xml · nonDerivative · entry 2 HOFFMAN ROBERT · CIK 0001166288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · price: Disposed of pursuant to merger agreement between issuer and Invitae Corporation in exchange for 5,752 shares of Invitae common stock having a market value of $7.86 per share on the effective date of the merger. Read SEC document |
| November 14, 2017 Filed Nov 16, 2017 22:53 UTC | CombiMatrix Corp CBMX · Entity 171845 | Disposition to issuerCommon Stock | 2,001 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-17-014225 · edgar.xml · nonDerivative · entry 1 HOFFMAN ROBERT · CIK 0001166288 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,618 F1 · price: Represents common stock of the issuer underlying restricted stock units that were cancelled in the merger pursuant to merger agreement between issuer and Invitae Corporation in exchange for 1,737 shares of Invitae common stock having a market value of $7.86 per share on the effective date of the merger. Read SEC document |
| October 31, 2017 Filed Dec 20, 2017 21:13 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | OtherCommon Stock | 536 | $13.05 | $6,993.46 |
DisclosureSEC source: 0001209191-17-066625 · doc4.xml · nonDerivative · entry 1 HOFFMAN ROBERT · CIK 0001166288 · CFO & SVP, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 536 F1 · kind: Represents shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan on October 31, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.